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ENGINEERING, EXPRESSION SCREENING, AND PRODUCTION CELL LINE DEVELOPMENT OF HETERO 
IG MOLECULES USING CHARGE PAIR MUTATIONS 
 
Jennitte Stevens1, Guna Kannan1, Trent Munro2 
 
1Biologics Optimization and 2Process Development, Amgen, Thousand Oaks 
 
In recent years, there has been an increase in therapeutic indications that require bispecific targeting.  Bispecific 
Hetero Ig antibodies that can target two antigens have long been considered as an attractive approach to drive 
synergistic biologic activity while maintaining the structure and stability of a traditional antibody.  However, clinical 
development of such molecules has been hampered by CMC related challenges relating to product heterogeneity. 
During the development of a Hetero Ig molecule targeting the Wnt pathway antagonists Dkk-1 and SCL-1, we 
employed a novel strategy to drive the heterodimerization of IgG antibodies through the addition of charge pair 
reside mutations (CPM) at both the heavy chain and light chain surface interface.  Through electrostatic 
interactions, these CPMs drive appropriate chain pairing, while minimizing undesired side products.  During 
engineering and expression in transient expression systems, we identified combinations of single residue pair 
mutations that promoted correct chain pairing. However, the combination of antibody pairs and expression balance 
is important to enable reduction in undesired side products.  These findings extend to stable cell line development, 
where vector design and appropriate analytics enable the identification of pools and then clones with desired 
product quality.  We have expanded this strategy for the development of a platform approach toward the efficient 
development of HeteroIg molecules.  
